SHR-A1811 Injection

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Shengjing Hospital

Conditions

Advanced Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-PositiveRecurrent or Metastatic Breast CancerHR Positive/HER2 Low Breast CancerMetastatic Gastric CancerRecurrent or Metastatic Cervical Cancer

Phase 2

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

RecruitingNCT06340230

Shengjing HospitalHR Positive/HER2 Low Breast Cancer

Start: 2024-08-23End: 2031-02-28Target: 93Updated: 2024-12-04

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

RecruitingNCT07051486

Jiangsu HengRui Medicine Co., Ltd.Recurrent or Metastatic Cervical Cancer

Start: 2025-10-11End: 2026-08-31Target: 60Updated: 2025-11-17

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

RecruitingNCT07102901

Jiangsu HengRui Medicine Co., Ltd.Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Cancer

Start: 2025-09-05End: 2027-12-31Target: 351Updated: 2025-09-10

Phase 3

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Active, not recruitingNCT06057610

Jiangsu HengRui Medicine Co., Ltd.HER2-PositiveRecurrent or Metastatic Breast Cancer

Start: 2023-10-16End: 2032-10-01Updated: 2026-03-11